Cost, causes and rates of rehospitalization of preterm infants

Journal of Perinatology

Volumn 27, Issue 10, 2007, Pages 614-619

  Underwood, M A ^a   Danielsen, B ^b   Gilbert, W M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Health and Information Solutions   (United States)

^c Women's Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ACUTE RESPIRATORY TRACT DISEASE; ARTICLE; COST OF ILLNESS; GESTATIONAL AGE; HEALTH CARE NEED; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITAL UTILIZATION; HUMAN; INFANT; INFANT DISEASE; LENGTH OF STAY; MAJOR CLINICAL STUDY; PREMATURITY; RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BIRTH WEIGHT; CALIFORNIA; GESTATIONAL AGE; HOSPITAL CHARGES; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LENGTH OF STAY; NEEDS ASSESSMENT; PATIENT READMISSION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; UTILIZATION REVIEW;

EID: 34848835483     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211801     Document Type: Article

References (26)

1. Lamarche-Vadel A, Blondel B, Truffert P, Burguet A, Cambonie G, Selton D et al. Re-hospitalization in infants younger than 29 weeks'gesatation in the EPIPAGE cohort. Acta Paediatr 2004; 93 1340-1345.
2. Petrou S, Sach T, Davidson L. The long term costs of preterm birth and low birth weight results of a systematic review. Child Care Health Dev 2001; 27: 97-115.
3. Schmitt SK, Sneed L, Phibbs CS. Costs of newborn care in California: A population-based study. Pediatrics 2006; 117: 154-160.
4. Gilbert WM, Nesbitt TS, Danielsen B. The cost of prematurity: quantification by gestational age and birth weight. Obstet Gynecol 2003; 102: 488-492.
5. Petrou S. Economic consequences of preterm birth and low birth weight. BJOG 2003; 110(Suppl 20): 17-23.
6. Tommiska V, Tuomnien R, Fellman V. Economic costs of care in extremely low birthweight infants during the first two years of life. Pediatr Crit Care Med 2003; 4: 157-163.
7. Petrou S, Mehta Z, Hockley C, Cook-Mozaffari P, Henderson J, Goldacre M. The impact of preterm birth on hospital inpatient admissions and costs during the first five years of life. Pediatrics 2003; 112: 1290-1297.
8. Morris BH, Gard CC, Kennedy K. Rehospitalization of extremely low birth weight infants: Are there racial/ethnic disparities? J Perinatol 2005; 25: 656-663.
9. Phibbs CS, Schmitt SK. Estimates of the cost and length of stay changes that can be attributed to one-week increases in gestational age for premature infants. Early Hum Dev 2006; 82: 85-92.
10. Williams RL, Creasy RK, Cunningham GC, Hawes WE, Norris FD, Tashiro M. Fetal growth and perinatal viability in California. Obstet Gynecol 1982; 59: 624-632.
11. Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. Pediatrics 2004; 114: 372-376.
12. Escobar GJ, Clark RH, Greene JD. Short-term outcomes of infants born at 35 and 36 weeks gestation: We need to ask more questions. Semin Perinatol 2006; 30: 28-33.
13. Elliott JP, Istwan NB, Jacques DL, Coleman SK, Stanziano GJ. Consequences of nonindicated preterm delivery in singleton gestations. J Reprod Med 2003; 48: 713-717.
14. Morris JM, Roberts CL, Crowther CA, Buchanan SL, Henderson-Smart DJ, Salkeld G. Protocol for the immediate delivery versus expectant care of women with preterm prelabour rupture of the membranes close to term (PPROMT) Trial. BMC Pregnancy Childbirth 2006; 6: 9.
15. Centers for Disease Control and Prevention, National Center for Infectious Diseases. Respiratory Syncytial Virus. 2004. Available at www.cdc.gov/ncidod/aip/research/rsv.html.
16. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537.
17. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Policy statement: Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV (RE9839). Pediatrics 1998; 102: 1211-1216.
18. Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program. Pediatrics 2004; 104: 1612-1619.
19. Vogel AM, Lennon DR, Broadbent R, Byrnes CA, Grimwood K, Mildenhall L et al. Palivizumab prophylaxis of respiratory syncytial virus in high-risk infants. J Paediatr Child Health 2002; 38: 550-554.
20. Heikkinen T, Valkonen H, Lehtonen L, Vainionpaa R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: Implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed 2005; 90: F64-F68.
21. Suresh S, Schilling S, Dakin C, Harris MA. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: A note of caution. J Paediatr Child Health 2003; 39: 637.
22. Farina D, Rodriguez SP, Bauer G, Novali L, Bouzas L, Gonzalez H et al. Respiratory syncytial virus prophylaxis: Cost-effective analysis in Argentina. Pediatr Infect Dis J 2002; 21: 287-291.
23. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in prematune infants in Germany. Eur J Pediatr 2003; 162: 237-244.
24. Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006; 160: 1070-1076.
25. Yasmeen S, Romano PS, Schembri ME, Keyzer JM, Gilbert WM. Accuracy of obstetric diagnoses and procedures in hospital discharge data. Am J Obstet Gynecol 2006; 194: 992-1001.
26. Romano PS, Yasmeen S, Schembri ME, Keyzer JM, Gilbert WM. Coding of perineal lacerations and other complications of obstetric care in hospital discharge data. Obstet Gynecol 2005; 106: 717-725.